Product Description
Mechanisms of Action: PPAR-a Agonist,PPAR-g Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Type 2 Diabetes|Dyslipidemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
---|---|---|---|---|---|---|---|
CV168-062 | P3 |
Completed |
Type 2 Diabetes |
2006-08-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
CV168-006 | P3 |
Completed |
Type 2 Diabetes |
2006-06-01 |
2019-03-21 |
Treatments |
|
CV168-026 | P3 |
Completed |
Type 2 Diabetes |
2006-05-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
CV168-048 | P3 |
Completed |
Type 2 Diabetes |
2006-03-01 |
2022-05-04 |
Primary Endpoints|Treatments |
|
CV168-021 | P3 |
Completed |
Type 2 Diabetes |
2005-11-01 |
2019-03-21 |
||
NCT00130806 | P3 |
Terminated |
Type 2 Diabetes |
2005-11-01 |
2022-05-04 |
||
CV168-025 | P3 |
Completed |
Type 2 Diabetes |
2005-03-01 |
2019-03-21 |
Treatments |
|
CV168-018 | P3 |
Completed |
Type 2 Diabetes |
None |
2019-03-21 |
Treatments |
|
CV168-022 | P3 |
Completed |
Type 2 Diabetes |
None |
2019-03-21 |
Treatments |
|
CV168-008 | P3 |
Completed |
Dyslipidemia |
None |
2019-03-21 |
Treatments |